Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RD3-like (RD3L), also known as TDRD9-AS1 or retinal degeneration protein 3-like, is annotated as a gene on chromosome 14 in humans and sometimes described as a protein-coding locus[5][7]. The nomenclature suggests a relation to RD3 (retinal degeneration 3 protein), which is a well-characterized regulatory protein critical in photoreceptor cell survival and guanylate cyclase trafficking in the eye[1][4][6]. However, RD3L itself lacks experimental evidence for a protein product, defined function, or relevance as a therapeutic target. According to current sources, TDRD9-AS1 is typically classified as a non-coding RNA (“TDRD9 antisense RNA 1 (non-protein coding)”), and there is no literature supporting a conserved, functional protein product or any known role in disease, cell signaling, or drug interaction[5][7]. Unlike RD3, which is associated with genetic retinal disease (such as LCA12) and acts as a regulator of guanylate cyclases in the retina[1][2][4][6], RD3L (RD3-like) does not appear in research as a functionally active molecule, receptor, or druggable target. The confusion arises due to the similarity in names, but RD3L does not correspond to RD3 and should not be conflated with it. As of current knowledge, RD3L is not recognized as a target in pharmacology, drug development, or clinical biomarkers. For the actual functional and clinically important protein, refer to "Retinal degeneration protein 3 (RD3)". Summary of issues: - RD3L is likely a non-coding RNA (TDRD9 antisense 1), not a protein-coding gene or receptor[5][7]. - RD3L is not a recognized therapeutic target and has no defined molecular or disease role. - The term “RD3 like” is ambiguous and does not map to a validated human drug target. - This entry appears to stem from gene annotation or automated prediction, not experimental validation. For therapeutic target information related to retinal degeneration, the search should focus on RD3 (Retinal degeneration protein 3), not RD3-like/RD3L.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RD3-like protein (RD3L).